AgenT

#Health / Well-being #Diagnostics

• Alzheimer
• Silent phase
• Diagnostics
• Preventative treatment
• Animal model

BACKGROUND

The development of AgenT’s exclusive and patented animal model began in 2012. Its inventor, Jérôme Braudeau, PhD in neurosciences, joined forces thereafter with Baptiste Billoir in 2016 to create AgenT in 2018.

DESCRIPTION OF THE PRODUCTS / SERVICES / TECHNOLOGY

The only way to find an effective treatment for Alzheimer’s disease is to concentrate on its silent phase (15 to 20 years before its diagnosis as currently practiced).

That is why AgenT is developing an unprecedented silent-phase blood test and treatments to prevent the development of symptoms

ACCOMPLISHMENTS / COLLABORATIONS / HIGHLIGHTS

AgenT’s animal model, the foundation of its activities, has been described in mice (Audrain et al, 2016) and rats (Audrain et al, 2017). The scientific aspects of the company’s vision were also validated in a 2018 publication (Souchet et al, 2018).

COLLABORATIONS SOUGHT

AgenT is actively searching for financial (campaign underway), academic and private partners to advance in the fight against Alzheimer’s disease.

• Further Information

  1 patent (+ 1 exclusive use license)

  STRENGHTS
  The only company working on the silent phase of Alzheimer’s disease and developing a diagnostic test and preventative treatments for deployment in that phase.

  AgenT has the only animal model accurately reproducing the clinical progression of Alzheimer’s disease, particularly in the silent phase.

  AgenT’s founders have renowned expertise in Alzheimer’s disease

  INNOVATION ASSETS
  A unique, disruptive animal model.